Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. StockNews.com raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Stock Down 1.9 %

NASDAQ:ESPR opened at $2.07 on Friday. The company has a market capitalization of $406.20 million, a PE ratio of -2.45 and a beta of 0.96. Esperion Therapeutics has a 52-week low of $0.87 and a 52-week high of $3.40. The stock’s 50 day moving average price is $1.91 and its 200 day moving average price is $2.13.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. As a group, sell-side analysts anticipate that Esperion Therapeutics will post -0.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ESPR. Capital Advisors Wealth Management LLC increased its position in Esperion Therapeutics by 22.9% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 5,000 shares during the period. Boomfish Wealth Group LLC raised its position in Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 5,102 shares in the last quarter. Summit Financial LLC lifted its holdings in Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 6,823 shares during the period. National Bank of Canada FI grew its stake in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Esperion Therapeutics by 45.3% in the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 11,658 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.